![Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases | Journal of Medicinal Chemistry Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/jm800988r/asset/images/medium/jm-2008-00988r_0003.gif)
Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases | Journal of Medicinal Chemistry
![Cancers | Free Full-Text | Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells Cancers | Free Full-Text | Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells](https://www.mdpi.com/cancers/cancers-14-01551/article_deploy/html/images/cancers-14-01551-g001.png)
Cancers | Free Full-Text | Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells
![IJMS | Free Full-Text | Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma IJMS | Free Full-Text | Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma](https://www.mdpi.com/ijms/ijms-23-00316/article_deploy/html/images/ijms-23-00316-g001.png)